The Relationship Between Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels and Treatment Response in Patients With Glomerulonephritis: A Single-Center Experience.
disease severity
glomerulonephritis
renal failure
supar
treatment response
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
accepted:
22
10
2023
medline:
29
11
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
Aim Soluble urokinase-type plasminogen activator receptor (suPAR) is an important protein that is reported to increase in a broad range of inflammatory processes. We aimed to determine whether suPAR is a significant biomarker in glomerulonephritis for distinguishing patients with treatment response from patients without treatment response in our study. Materials and methods This was a prospective study in which 117 patients with biopsy-proven glomerulonephritis and 54 healthy individuals without a known chronic disease (control group) were enrolled. A total of 117 patients were divided into two groups: "treatment responsive" and "treatment nonresponsive." Blood samples were collected from the patients upon their outpatient clinic visits, and the demographical and lab parameters were compared between the groups. Results For the patient group consisting of 117 individuals, 56.4% were male, the mean age was 49.6 years, and the mean follow-up duration was 32.2 months. The most commonly diagnosed glomerular disease was focal segmental glomerulosclerosis (FSGS), followed by IgA nephropathy and membranoproliferative glomerulonephritis, respectively. While suPAR levels were significantly higher in the patient group (166.06 ± 127.66 vs. 119.67 ± 70.53 pg/ml, p = 0.001) (suPAR level ± standard deviation), no significant relationship was found between suPAR levels, treatment response status, and disease severity. Besides, there was no significant relationship between suPAR levels and proteinuria levels, BMI of the patients, and the type of immunosuppressive agent used in the treatment and BMI. Conclusion Our study showed that suPAR levels could distinguish a patient with glomerulonephritis from a healthy individual, whereas it has no value in predicting the disease progression and treatment responsiveness.
Identifiants
pubmed: 38021795
doi: 10.7759/cureus.47473
pmc: PMC10662779
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e47473Informations de copyright
Copyright © 2023, İşsever et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Nephrology (Carlton). 2018 Nov;23(11):991-996
pubmed: 28817218
J Bras Pneumol. 2018 Jan-Feb;44(1):36-41
pubmed: 29538541
Kidney Int Rep. 2021 Jan 06;6(3):685-694
pubmed: 33732983
Int J Cardiol. 2017 Feb 1;228:158-161
pubmed: 27865178
Nat Rev Immunol. 2023 Jul;23(7):453-471
pubmed: 36635359
J Am Soc Nephrol. 2012 Dec;23(12):2051-9
pubmed: 23138488
Transplantation. 2013 Oct 15;96(7):649-56
pubmed: 23842190
Dis Markers. 2009;27(3):157-72
pubmed: 19893210
Medicine (Baltimore). 2019 Sep;98(38):e17146
pubmed: 31567954
Acta Crystallogr D Biol Crystallogr. 2005 Jun;61(Pt 6):697-700
pubmed: 15930623
Clin Chim Acta. 2015 Apr 15;444:234-41
pubmed: 25704300
Minerva Pediatr. 2019 Feb;71(1):4-11
pubmed: 27070416
Nat Med. 2011 Jul 31;17(8):952-60
pubmed: 21804539
Int J Mycobacteriol. 2019 Jul-Sep;8(3):262-266
pubmed: 31512602
J Intern Med. 2010 Sep;268(3):296-308
pubmed: 20561148
Clin J Am Soc Nephrol. 2014 Nov 7;9(11):1903-11
pubmed: 25318750
Int J Tuberc Lung Dis. 2019 Nov 1;23(11):1155-1161
pubmed: 31718751
Turk J Haematol. 2016 Jun 5;33(2):135-40
pubmed: 26376588
Acta Pharmacol Sin. 2018 Jul;39(7):1189-1196
pubmed: 29239349